Sodium in the Skin and Atopic Dermatitis
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT06998446
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above. The study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether skin sodium concentration is linked to atopic dermatitis and immune profiles over time. Participants will be asked to complete questionnaires, provide bio samples, and undergo non-contrast sodium MRI at 2-3 time points over 3-24 months.
Key Dates
- Start date
- May 12, 2025
- Status verified
- May 2025
- Primary completion
- Aug 30, 2028
- Completion
- Aug 30, 2028
Study Design
- Enrollment
- 90 participants (estimated)
Arms
- Arm: No History of ADHealthy controls
- Arm: Mild ADEczema Area Severity Index (EASI): scores \<7 will be considered mild AD
- Arm: Severe ADEczema Area Severity Index (EASI): scores \>21 will be considered severe
Primary Outcome Measure
Skin sodium concentration [ Time Frame: 2 years ]
Central Contacts
- Jie Zhu, MD415-502-0433
- Katrina Abuabara, MD415-514-9769
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| San Francisco VA Medical Center | San Francisco | California | 94115 | Theodora Mauro, MD (PRINCIPAL_INVESTIGATOR) |
| UCSF Mt Zion Campus | San Francisco | California | 94511 |
Find similar trials in San Francisco, CA
By condition
By specialty
Related Studies
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- Molecular Signatures of Cutaneous Dupilumab ResponsePHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
- Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECTRecruiting · University of California, San Diego · La Jolla, California
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama